共查询到20条相似文献,搜索用时 31 毫秒
1.
In the treatment of osteoporosis, the aim of the antiresorptive therapy is to restore bone density by decreasing bone remodeling. The process of bone remodeling plays a role in plasma calcium homeostasis and serves to modify bone architecture in order to meet changing mechanical needs, to maintain osteocyte viability, and to repair microdamage in bone matrix. Estrogen deficiency results in a number of detrimental effects on bone, including suppression of osteocyte survival as well as impairment of osteoblast response to mechanical stimuli and repair of ageing bone. In this review, effects of available antiresorptive therapies on endocrine regulations of bone metabolism in postmenopausal osteoporosis are compared. The aim of antiresorptive treatment is to ensure adequate bone remodeling, reparation of microdamage of bone, and increased bone strength. Ideally, this effect should be maintained long-term. Several agents are approved for the treatment of osteoporosis. Calcitonin transiently inhibits osteoclast activity without decreasing osteoblast collagen synthesis. Aminobisphosphonates decrease bone remodeling by decreasing osteoclast activity and by inducing osteoclast apoptosis. This allows more time for secondary mineralization to proceed to completion in the existing bone tissue mass, so increasing the mechanical resistance of bone to loading. Estrogens and raloxifene (a selective estrogen receptor modulator that acts as an estrogen agonist in bone) suppress bone remodeling to the premenopausal range, maintaining the function of osteoblasts and osteocytes. In the placebo-controlled osteoporosis treatment trials, all the above treatments reduced the risk of fractures. Raloxifene therapy was also associated with a favorable or neutral effect in the cardiovascular system, and a reduced incidence of breast cancer. Selection of appropriate drug for treatment of postmenopausal osteoporosis should take into account the long-term effect of the antiresorptive agent on bone. Moreover, the effects on other tissues ++should also be considered, and this encompasses both safety concerns, as well as the potentially beneficial effects on other tissues. Further investigation is needed to evaluate the different modes of action of these agents, and their long-term effects on bone and other tissues. 相似文献
2.
Cosman F 《Current rheumatology reports》2006,8(1):63-69
Recombinant human parathyroid hormone (PTH 1–34) is the only anabolic agent currently approved for the treatment of osteoporosis.
The term anabolic is based on mechanism of action. PTH stimulates bone formation, in contrast to antiresorptive agents, which
reduce bone resorption and formation. Recent investigations involving the PTH(1-34) and PTH(1-84) peptides, alone and in combination
or sequential regimens with antiresorptive agents, have provided a greater understanding of the place of PTH in the armamentarium
against osteoporosis. These studies indicate that adding a bisphosphonate to PTH in previously untreated individuals does
not produce additional bone benefit; however, sequential use of PTH followed-up by an antiresorptive agent is highly effective
at increasing bone mineral density. Adding PTH after an antiresorptive agent also produces substantial bone density increments,
though the magnitude of bone density increase may differ for different antiresorptive agents. PTH can repair underlying micro-architectural
defects in bone, improve bone mass substantially, and perhaps change macro-architecture and geometry of bone. There are still
many unanswered questions regarding PTH treatment of osteoporosis, including the optimal duration of treatment, optimal dosing
regimen, mechanism of resistance to its effect after 18–24 months, and the effect of subsequent rechallenge. 相似文献
3.
Sone T 《Clinical calcium》2003,13(4):473-477
The accelerated bone resorption contributes significantly to the pathophysiology of diseases such as osteoporosis, Paget's disease, hypercalcemia, bone metastasis, and inflammation of bone associated with rheumatoid arthritis. Several antiresorptive agents have been validated as a means to control bone resorption in these diseases. A recent understanding of the molecular mechanism of osteoclastic bone resorption is providing opportunities for developing novel antiresorptive agents. 相似文献
4.
New anabolic therapies in osteoporosis 总被引:3,自引:0,他引:3
While antiresorptive drugs have been the cornerstone of osteoporosis therapy, anabolic drugs are an important new advance in the treatment of osteoporosis. By directly stimulating bone formation, anabolic agents might have greater potential than the antiresorptives to increase bone mass and to decrease fractures. It is also possible that the combination of an antiresorptive agent with an anabolic agent could be more potent than either agent alone. Potential anabolic therapies for osteoporosis, including fluoride, growth hormone, insulin-like growth factor-I, strontium, and parathyroid hormone, are reviewed here. Of these, parathyroid hormone has clearly emerged as the most promising treatment at this time. 相似文献
5.
The role of selective estrogen receptor modulators in the prevention and treatment of osteoporosis 总被引:5,自引:0,他引:5
Osteoporosis can affect almost everyone in the population, and although clinical outcome of fracture is manifested in late life, the disease process begins in the early postmenopausal years in women. The pharmacologic agents currently available for osteoporosis prevention and treatment act by inhibiting bone resorption, and include estrogen or hormone replacement therapy (estrogen with progestin), bisphosphonates, salmon calcitonin nasal spray, and selective estrogen receptor modulators (SERMs). Raloxifene is a benzothiophene SERM that has estrogen against effects in bone and on serum lipid metabolism and estrogen antagonist effects on breast and uterine tissue. This article summarizes the effects of these antiresorptive agents, as measured by changes in bone mineral density, biochemical markers of bone turnover, and incident fractures in postmenopausal osteoporosis. 相似文献
6.
Antiresorptive therapies are used to increase bone strength in individuals with osteoporosis and include five principal classes of agents: bisphosphonates, estrogens, selective estrogen receptor modulators (SERMs), calcitonin and monoclonal antibodies such as denosumab. However, no head-to-head studies have compared different antiresorptive agents using fracture as an end point. Bisphosphonates, which have proven antifracture efficacy and a good safety profile, are the most widely used first-line antiresorptive therapy and are recommended for patients with osteoporosis, a prior fragility fracture or osteopenia, as well as individuals with a high risk of fracture. Denosumab, which also has good antifracture efficacy, is another possible first-line therapy, although long-term safety data are lacking. However, no single antiresorptive therapy is currently appropriate for all patients or clearly superior to other therapies. Antiresorptive agents such as estrogens, SERMs (in postmenopausal women) and calcitonin are considered to be second-line agents that are appropriate in special circumstances. Clinicians should determine the most appropriate pharmacological therapy after a careful assessment of the risk:benefit profiles of these drugs in each patient. In addition, patients should receive a detailed explanation of the treatment goals, so that the therapeutic benefit can be maximized through good compliance and persistence. 相似文献
7.
The use of parathyroid hormone in the treatment of osteoporosis 总被引:1,自引:0,他引:1
Anabolic skeletal agents have recently broadened our therapeutic options for osteoporosis. By directly stimulating bone formation,
they reduce fracture incidence by improving bone qualities in addition to increasing bone mass. Teriparatide [recombinant
human parathyroid hormone(1–34)], the only anabolic agent currently approved in the United States for osteoporosis, has emerged
as a major therapeutic approach to selected patients with osteoporosis. Teriparatide is approved for both postmenopausal women
and men with osteoporosis who are at high risk for fracture. With the use of this anabolic agent, bone density and bone turnover
increase, microarchitecture improves, and bone size is beneficially altered. The incidence of vertebral and nonvertebral fractures
is reduced with teriparatide use. Combination therapy with parathyroid hormone and an antiresorptive does not appear to offer
definitive advantages over the use of PTH or an antiresorptive alone, although recent ideas about combining these agents may
offer new insights. In order to maintain increases in bone density acquired during PTH therapy, it is important to follow
its use with an antiresorptive agent. 相似文献
8.
Mary L. Bouxsein PhD 《Clinical reviews in bone and mineral metabolism》2006,4(3):143-153
There is increasing evidence that fracture risk in osteoporosis is not only related to bone mineral density but also to a
compilation of factors that are often referred to under the legendary terminology “bone quality”. This article reviews initially
the biomechanical aspects of trauma and then the current understanding of the many characteristics of bone that give it strength
to resist trauma, including those characteristics that can currently be measured in vivo, those that will shortly be assessable,
and those that yet defy measurement in the intact human. The mechanism by which antiresorptive and anabolic therapies for
osteoporosis may affect bone strength are also discussed. 相似文献
9.
Combination therapy for postmenopausal osteoporosis 总被引:1,自引:0,他引:1
A number of agents have been shown to reduce the risk of fractures in patients with postmenopausal osteoporosis. However, the additional benefits of combination therapy as opposed to monotherapy are uncertain. We performed a MEDLINE search and reviewed the published randomized trials of agents used in combination. Combination therapy results in greater gains in bone mineral density than monotherapy and possibly greater effects on bone turnover. However, none of these studies are large enough or of sufficient duration to determine whether a greater reduction in fracture is achieved. Combination therapy has important cost implications and is likely to be associated with an increased prevalence of adverse events, reduced tolerability and a reduction in adherence. Furthermore, over-suppression of bone turnover as a result of combination antiresorptive therapy might have adverse effects on bone strength, particularly with long-term treatment. Thus, the use of combination therapy for treatment of osteoporosis cannot be recommended on the basis of currently available evidence. 相似文献
10.
In order to improve the reproducibility of bone mineral measurement, measurement needs to be repeated on the same position of the patients. Although lumbar bone mineral measurement is recommended in post menopausal osteoporosis, peripheral bone mineral reduction may precede lumbar bone mineral reduction in some secondary osteoporosis. The antiresorptive agents increase lumbar or proximal femoral bone mineral density; however, little changes are observed in peripheral bone mineral density by the treatment. 相似文献
11.
夏维波 《中华骨质疏松和骨矿盐疾病杂志》2011,4(2):73-81
联合和序贯治疗骨质疏松症是为了追求更大疗效的一种选择,本文检索分析近45年来发表的此类临床研究结果。目前尚无证据表明两种抗骨吸收联合治疗有降低骨折发生率的叠加作用(如双膦酸盐加ERT或雷洛昔芬,雌激素加降钙素),仅观察到联合治疗可以降低骨转换和增加骨密度的结果。联合甲状腺激素(PTH)同抗骨吸收药物,随着药物的不同对骨密度的效果各异。在停止使用促进骨形成剂PTH后序贯使用双膦酸盐、雷洛昔芬或锶盐,可以防止因停用PTH后的骨丢失,可能成为未来治疗严重的绝经后骨质疏松症的重要选择。 相似文献
12.
The recent decade has seen the emergence of a wide variety of new effective therapies for osteoporosis. Although hormone replacement
therapy and calcium supplementation were the only available therapies 20 yr ago, we now have a wide variety of anticatabolic
(antiresorptive) therapies (bisphosphonates, calcitonin, selective estrogen receptor modulators [SERMs]) and anabolic therapies
in the form of recombinant parathyroid hormone [PTH(1–34) and PTH(1–84)] approved and commercially available. Our initial
perceptions around these therapies were quite primitive, being mainly based on bone mineral density measurements. However,
recent progress in imaging technology and structural and histological evaluation of bone has yielded important new insights
into the mechanism of action of the various treatments. This article summarizes current knowledge about both anticatabolic
and the more recent anabolic therapies, with special emphasis on the results obtained from histological and structural analyses
of bone biopsies.
The evidence currently available indicates that anticatabolic therapies exert their significant antifracture efficacy through
a pronounced reduction of bone turnover. This reduction in remodeling activity causes preservation of trabecular structure
and a decrease in cortical porosity, both effects that will preserve bone biomechanical strength. Although anticatabolic drugs
preserve bone architecture, bone-forming (anabolic) therapies, in this context exemplified by PTH, are able to reverse the
deterioration of cancellous and cortical bone architecture seen during age-dependent bone loss and osteoporosis. Recent analyses
using techniques enabling analysis of bone matrix constituents suggest that both anticatabolic and anabolic therapies also
alter the properties of bone tissue components like mineralization and collagen crosslinking. 相似文献
13.
Boonen S Marin F Obermayer-Pietsch B Simões ME Barker C Glass EV Hadji P Lyritis G Oertel H Nickelsen T McCloskey EV;EUROFORS Investigators 《The Journal of clinical endocrinology and metabolism》2008,93(3):852-860
INTRODUCTION: EUROFORS was a 2-yr prospective, randomized trial of postmenopausal women with established osteoporosis, designed to investigate various sequential treatments after teriparatide 20 microg/d for 1 yr. The present secondary analysis examined the effects of 2 yr of open-label teriparatide in women previously treated with antiresorptive drugs for at least 1 yr. METHODS: A subgroup of 245 women with osteoporosis who had 2 yr of teriparatide treatment were stratified by previous predominant antiresorptive treatment into four groups: alendronate (n=107), risedronate (n=59), etidronate (n=30), and non-bisphosphonate (n=49). Bone mineral density (BMD) at the lumbar spine and hip was determined after 6, 12, 18, and 24 months, and bone formation markers were measured after 1 and 6 months. RESULTS: Significant increases in bone formation markers occurred in all groups after 1 month of teriparatide treatment. Lumbar spine BMD increased at all visits, whereas a transient decrease in hip BMD, which was subsequently reversed, was observed in all groups. BMD responses were similar in all previous antiresorptive groups. Previous etidronate users showed a higher increase at the spine but not at the hip BMD. Duration of previous antiresorptive therapy and lag time between stopping previous therapy and starting teriparatide did not affect the BMD response at any skeletal site. Treatment-emergent adverse events were similar to those reported in treatment-naive postmenopausal women with osteoporosis treated with teriparatide. CONCLUSIONS: Teriparatide induces positive effects on BMD and markers of bone formation in postmenopausal women with established osteoporosis, regardless of previous long-term exposure to antiresorptive therapies. 相似文献
14.
Compston J 《Endocrine》2002,17(1):21-27
Conclusion Histomorphometric studies have made an important contribution to our understanding of how pharmacologic interventions affect
BMD and bone strength in patients with osteoporosis. For antiresorptive agents, the therapeutic effect is mediated predominantly
by suppression of bone turnover; in the case of more potent antiresorptive agents, changes in secondary mineralization also
occur that affect BMD and, potentially, bone strength. The mechanisms by which anabolic agents increase BMD and reduce fracture
risk include de novo bone formation and induction of a positive remodeling balance. The relationship between BMD and bone strength is influenced
by different factors in the case of anti-resorptive and anabolic agents, and the relative antifracture efficacy of the two
approaches at both vertebral and non-vertebral sites requires further study. 相似文献
15.
Reem Smoum Arik Bar Bo Tan Garry Milman Malka Attar-Namdar Orr Ofek Jordyn M. Stuart Alon Bajayo Joseph Tam Vardit Kram David O'Dell Michael J. Walker Heather B. Bradshaw Itai Bab Raphael Mechoulam 《Proceedings of the National Academy of Sciences of the United States of America》2010,107(41):17710-17715
Bone mass is determined by a continuous remodeling process, whereby the mineralized matrix is being removed by osteoclasts and subsequently replaced with newly formed bone tissue produced by osteoblasts. Here we report the presence of endogenous amides of long-chain fatty acids with amino acids or with ethanolamine (N-acyl amides) in mouse bone. Of these compounds, N-oleoyl-l-serine (OS) had the highest activity in an osteoblast proliferation assay. In these cells, OS triggers a Gi-protein-coupled receptor and Erk1/2. It also mitigates osteoclast number by promoting osteoclast apoptosis through the inhibition of Erk1/2 phosphorylation and receptor activator of nuclear-κB ligand (RANKL) expression in bone marrow stromal cells and osteoblasts. In intact mice, OS moderately increases bone volume density mainly by inhibiting bone resorption. However, in a mouse ovariectomy (OVX) model for osteoporosis, OS effectively rescues bone loss by increasing bone formation and markedly restraining bone resorption. The differential effect of exogenous OS in the OVX vs. intact animals is apparently a result of an OVX-induced decrease in skeletal OS levels. These data show that OS is a previously unexplored lipid regulator of bone remodeling. It represents a lead to antiosteoporotic drug discovery, advantageous to currently available therapies, which are essentially either proformative or antiresorptive. 相似文献
16.
PURPOSE OF REVIEW: The prevention and treatment of osteoporosis has traditionally involved the use of antiresorptive therapies. The introduction of parathyroid hormone, an anabolic agent that enhances bone formation, has been accompanied by new treatment strategies. This article reviews combination and sequential therapy approaches with parathyroid hormone and antiresorptive agents to optimize efficacy outcomes. RECENT FINDINGS: The distinguishing features of the anabolic and antiresorptive therapies for the treatment of osteoporosis has led to the hypothesis that the appropriate use of both agents, either in sequence or in combination, may result in superior fracture protection compared with either anabolic or antiresorptive treatment alone. This enthusiasm has been tempered by the observations that the transition from daily bisphosphonate therapy may blunt the efficacy of teriparatide. By contrast, more recent studies suggest that once-weekly bisphosphonate therapy may provide a better option with parathyroid hormone either in combination or in sequence. These considerations are critical to understanding the benefits of sequential treatment (parathyroid hormone followed by an antiresorptive agent), which aims to maintain or build on the large gains in efficacy from short-term therapy with parathyroid hormone. Because patients may require an additional treatment course of parathyroid hormone in the future, the choice of antiresorptive agent should be carefully considered. In addition, more recent evidence suggests that the forms of parathyroid hormone may have important differences in action that influence combination and sequence outcomes. SUMMARY: Combination and sequential therapy with parathyroid hormone offers new options to maximize efficacy in patients at risk for osteoporotic fracture. 相似文献
17.
Antiresorptive agents for osteoporosis are a cornerstone of therapy, but anabolic drugs have recently widened our therapeutic options. By directly stimulating bone formation, anabolic agents reduce fracture incidence by improving other bone qualities in addition to increasing bone mass. Teriparatide (human parathyroid hormone[1-34]) has clearly emerged as a major approach for selected patients with osteoporosis. Teriparatide increases bone mineral density and bone turnover, improves bone microarchitecture, and changes bone size. The incidence of vertebral and non-vertebral fractures is reduced. Teriparatide is approved in many countries throughout the world for the treatment of both postmenopausal women and men with osteoporosis who are at high risk for fracture. Another anabolic agent, strontium ranelate, may both promote bone formation and inhibit bone resorption. Clinical trials support the use of strontium ranelate as a treatment for postmenopausal osteoporosis and have shown that strontium ranelate reduces the frequency of vertebral and non-vertebral fractures. Other potential anabolic therapies for osteoporosis, including other forms of parathyroid hormone, growth hormone, and insulin-like growth factor-I, have been examined, although less data are currently available on these approaches. 相似文献
18.
Oral antiresorptive therapy 总被引:1,自引:0,他引:1
Oral antiresorptive agents play a pivotal role in the management of osteoporosis. This paper discusses the effects and potential
future role of newer agents such as ibandronate. Alternative dosing schedules and routes of administration have become available
and may improve fracture protection, compliance, and tolerability for the long term treatment of a chronic condition such
as osteoporosis. Increasingly these agents are being used to reduce bone loss in other diseases associated with high risk
for osteoporosis such as organ transplantation and cystic fibrosis. Such studies may act as prototypes for the extended use
of this class of drugs in other chronic inflammatory disease states. The innovative, yet disappointing results from combining
an antiresorptive agent (alendronate) with the anabolic effects of teriparatide is also discussed. The major problem that
remains is the lack of direct comparison between the agents in terms of fracture endpoints. 相似文献
19.
Opinion statement The pathogenesis of osteoporosis in chronic liver disease and post-liver transplantation is complex and heterogeneous. The
development of hepatic osteodystrophy may be related to both increased bone resorption and decreased bone formation. Available
medical treatments can be broadly classified into antiresorptive and bone-stimulating agents. Most published studies on the
treatment of osteoporosis in patients with liver disease have used the commonly prescribed antiosteoporosis drugs approved
for postmenopausal osteoporosis. These studies have included a small number of subjects and used bone mineral density (BMD)
changes rather than fracture occurrence as an endpoint because of the short follow-up. Although the increases in BMD are promising,
no intervention is proven to have antifracture efficacy in hepatic osteodystrophy. The natural history of bone disease following
liver transplantation has not been fully investigated, although studies suggest that bone mineral loss is transient and generally
reverses within a year following transplantation. The approach to treatment in liver transplant recipients should be targeted
at preventing the early bone loss without interfering with the later recovery. Based on the available data, no single available
agent can be considered as first-line therapy. In our opinion, the best treatment approach involves the elucidation of modifiable
risk factors and the selection of agents targeted at the underlying derangements. 相似文献
20.
Stĕpán J 《Vnitr?ní lékar?ství》2007,53(3):293-299
The aim of this article is to justify a need for evaluation of the absolute risk of fractures, to compare efficacy of antiresorptive therapies as indicated by large clinical trials, and to review currently available methods to assess efficacy of therapies in individual patients. It is emphasized that adherence to therapies is influenced not only by the individual bone efficacy and safety of the drug but also by beneficial impacts of the treatment on tissues other than bone. 相似文献